Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy

類似資料

• Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma
  著者:: Punke, Alexandra P., 等
  出版事項: (2017)
• Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone
  著者:: Saboo, Sachin S., 等
  出版事項: (2012)
• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma.
  著者:: Attal, Michel, 等
  出版事項: (2017)
• Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
  著者:: Voorhees, Peter M., 等
  出版事項: (2020)
• A Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Ineligible Multiple Myeloma
  著者:: O’Donnell, Elizabeth K., 等
  出版事項: (2018)